drugset / Trial / NCT04063215
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
Phase 1/2
Completed
24 enrolled
Hope Biosciences LLC
The University of Texas Health Science Center, Houston · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury in adults.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2024-10-25
- Completion
- 2024-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB-adMSCs | Cell therapy | 2e+08 cells | Other |